Discrete macular cell layers correlated with visual sensitivity loss

Article

Macular inner retinal layer (mIRL) is linked to visual sensitivity in glaucoma patients

Macular inner retinal layer (mIRL) is linked to visual sensitivity in glaucoma patients, according to a study featured in Eye.

A team led by Dr T. S. Varjaranant, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Illinois, USA, compared the thickness of discrete macular cell layers, the thickness of the retinal nerve fibre layer (mRNFL) and visual field sensitivity between 28 glaucoma patients and 22 control patients. Stratus optical coherence tomography macular scans were used to measure thickness of macular retinal nerve fibre layer (mRNFL), macular inner retinal layer (mIRL) and macular outer retinal layer (mORL). Visual sensitivity loss was calculated by mean deviation (MD) using Humphrey Visual Field Analyser. To evaluate structure–function, a mixed model analysis was used.

The findings demonstrated that the mean mIRL thickness was significantly lower in advanced glaucoma than in the control group. Mean mIRL thickness was strongly linked to MD. There were no significant results recorded between mean mORL thickness in early and advanced glaucoma and the control group.

Although there was no difference in macular structure–function between advanced and early glaucoma, both glaucoma groups showed that mIRL thickness was related to visual sensitivity loss.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.